| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 19.74B | 20.39B | 20.83B | 23.51B | 21.11B | 18.71B |
| Gross Profit | 6.49B | 5.91B | 7.82B | 2.35B | 6.09B | 4.89B |
| EBITDA | 1.71B | 2.30B | 2.47B | 1.60B | 1.65B | 1.74B |
| Net Income | 609.50M | 1.01B | 1.15B | 601.60M | 662.43M | 647.56M |
Balance Sheet | ||||||
| Total Assets | 19.50B | 23.11B | 21.99B | 19.51B | 17.79B | 16.81B |
| Cash, Cash Equivalents and Short-Term Investments | 5.06B | 996.90M | 554.16M | 3.22B | 318.73M | 803.60M |
| Total Debt | 3.02B | 5.34B | 5.29B | 5.10B | 5.66B | 5.08B |
| Total Liabilities | 10.38B | 14.12B | 13.84B | 12.34B | 11.07B | 10.64B |
| Stockholders Equity | 9.12B | 8.99B | 8.15B | 7.17B | 6.72B | 6.17B |
Cash Flow | ||||||
| Free Cash Flow | 2.83B | 432.10M | 409.06M | 1.16B | -757.58M | 1.68B |
| Operating Cash Flow | 3.21B | 1.22B | 766.36M | 1.69B | 590.26M | 2.25B |
| Investing Cash Flow | -535.20M | -933.52M | -432.53M | -678.80M | -711.52M | -983.93M |
| Financing Cash Flow | -2.68B | -133.82M | -223.99M | -1.01B | 4.98M | -1.50B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | ₹23.75B | 8.71 | ― | 2.00% | 17.71% | 18.17% | |
67 Neutral | ₹97.54B | 19.77 | ― | 0.79% | 9.74% | -6.32% | |
66 Neutral | ₹4.29B | 11.08 | ― | 1.19% | -3.72% | -50.02% | |
66 Neutral | ₹45.01B | 23.32 | ― | 0.35% | -7.81% | -6.64% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
54 Neutral | ₹75.06B | 25.39 | ― | 0.63% | 14.75% | -15.81% | |
46 Neutral | ₹50.04B | -36.29 | ― | ― | -18.81% | -57.61% |
DCM Shriram Industries Limited has notified the stock exchanges that it has issued guidance to shareholders on how to apportion the cost of acquisition of their equity holdings in the company and its two resulting entities, DCM Shriram Fine Chemicals Limited and DCM Shriram International Limited, following a court-approved composite scheme of arrangement. The scheme, which became effective on December 17, 2025, involved the amalgamation of Lily Commercial Private Limited into DCM Shriram Industries and the demerger of its chemical and rayon undertakings into two separate resulting companies, with shareholders receiving one share in each resulting company for every share held in the demerged company as of the record date; the communication aims to clarify tax and accounting treatment for investors and underscores a restructuring intended to sharpen business focus and potentially unlock value across the distinct business verticals.
DCM Shriram Industries Limited has informed shareholders and the stock exchanges that, under its ongoing composite scheme of arrangement, the record date for determining eligibility for share allotment in its resultant companies DCM Shriram Fine Chemicals Limited and DCM Shriram International Limited has been revised from 19 December 2025 to 26 December 2025, due to pending formalities related to extinguishment and allotment of shares of a transferor company. Eligible shareholders on the new record date will receive one fully paid equity share of face value ₹2 each in both DCM Shriram Fine Chemicals and DCM Shriram International for every one fully paid equity share of ₹2 held in DCM Shriram Industries, though these new shares will remain non-tradable until listing and trading permissions are granted by BSE and NSE, a process expected to take about 45–60 days after the requisite applications are filed, temporarily affecting liquidity but clarifying the timeline and terms for stakeholders awaiting the scheme’s implementation.